| abstract |
The present invention relates to a hydrogel for in-vivo release of medication comprising at least one medication, wherein the hydrogel comprises (i) a protein-based biopolymer functionalized with a functionalisation agent that is able to form guest-host interactions with oxidized β-cyclodextrin, preferably a primary aminoalkylphenol, more preferably gelatin functionalized with tyramine (GTA) and (ii) oxidized β-cyclodextrin (oβ-CD), wherein the hydrogel is cross-linked via exposure to visible light in presence of a biocompatible photoinitiator, resulting in a degree of swelling in the range of 2-20 calculated as (swollen weight – dry weight)/dry weight. It further relates to a method for its preparation, as well as to a medication for treatment of musculoskeletal disorders, preferably for treatment of infection, inflammation, malignant processes, growth disorders, degenerative disorders or treatment of pain arising from (surgical treatment of) these disorders. |